<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34507935</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1473-4893</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>21</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical medicine (London, England)</Title>
          <ISOAbbreviation>Clin Med (Lond)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acute myocarditis: aetiology, diagnosis and management.</ArticleTitle>
        <Pagination>
          <StartPage>e505</StartPage>
          <EndPage>e510</EndPage>
          <MedlinePgn>e505-e510</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.7861/clinmed.2021-0121</ELocationID>
        <Abstract>
          <AbstractText>Acute myocarditis is a serious, likely underdiagnosed condition affecting people of all ages and for which the number of UK hospital admissions is rising. A primary diagnosis of myocarditis accounted for 0.04% (36.5 per 100,000) of all hospital admissions in England between 1998 and 2017, although this is likely to be an underestimate of the true burden of myocarditis. The aetiology is broad, including infective and inflammatory conditions as well as exposure to toxic agents. Clinical features are varied and overlap with other acute cardiac conditions making diagnosis a challenge. Cardiovascular magnetic resonance imaging currently serves as the gold standard non-invasive diagnostic modality. If an underlying aetiological process is identified, then therapy may be directed at the cause; however, for most, treatment is supportive and aimed at managing any complications such as heart failure or arrhythmias. There is emerging evidence for immunosuppressive therapy in certain cases. Prognosis is generally good with recovery in most; however, up to 30% with biopsy-proven myocarditis progress to develop a dilated cardiomyopathy and its potential associated complications. All-cause mortality in the UK for patients presenting to hospital with acute myocarditis is approximately 4%.</AbstractText>
          <CopyrightInformation>© Royal College of Physicians 2021. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lampejo</LastName>
            <ForeName>Temi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Imperial College Healthcare NHS Trust, London, UK temi.lampejo@nhs.net.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Durkin</LastName>
            <ForeName>Simon M</ForeName>
            <Initials>SM</Initials>
            <AffiliationInfo>
              <Affiliation>Imperial College Healthcare NHS Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhatt</LastName>
            <ForeName>Naman</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>London North West University Healthcare NHS Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guttmann</LastName>
            <ForeName>Oliver</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Barts Health NHS Trust, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Med (Lond)</MedlineTA>
        <NlmUniqueID>101092853</NlmUniqueID>
        <ISSNLinking>1470-2118</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002311" MajorTopicYN="Y">Cardiomyopathy, Dilated</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">cardiac inflammation</Keyword>
        <Keyword MajorTopicYN="Y">chest pain</Keyword>
        <Keyword MajorTopicYN="Y">myocarditis</Keyword>
        <Keyword MajorTopicYN="Y">myopericarditis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>11</Day>
          <Hour>5</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34507935</ArticleId>
        <ArticleId IdType="pmc">PMC8439515</ArticleId>
        <ArticleId IdType="doi">10.7861/clinmed.2021-0121</ArticleId>
        <ArticleId IdType="pii">21/5/e505</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Global Burden of Disease Study 2013 Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet
2015;386:743–800</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4561509</ArticleId>
            <ArticleId IdType="pubmed">26063472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lota AS, Halliday B, Tayal U.
et al.
Epidemiological trends and outcomes of acute myocarditis in the National Health Service of England. Circulation
2019;140:A11463. https://www.ahajournals.org/doi/10.1161/circ.140.suppl_1.11463</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/circ.140.suppl_1.11463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirati E, Frigerio M, Adler ED.
et al.
Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail
2020;663–87.</Citation>
        </Reference>
        <Reference>
          <Citation>Aretz HT, Billingham ME, Edwards WD.
et al.
Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol
1987;1:3–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3455232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio ALP, Calabrese F, Angelini A.
et al.
A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and ­aetiopathogenetic features at diagnosis. Eur Heart J
2007;28:1326–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17493945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sen-Chowdhry S, Syrris P, Prasad SK.
et al.
Left-dominant arrhythmogenic cardiomyopathy. An under-recognized clinical entity. J Am Coll Cardiol
2008;52:2175–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19095136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirati E, Cipriani M, Moro C.
et al.
Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis multicenter Lombardy registry. Circulation
2018;138:1088–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29764898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Younis A, Matetzky S, Mulla W.
et al.
Epidemiology characteristics and outcome of patients with clinically diagnosed acute myocarditis. Am J Med
2020;133:492–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31712098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aquaro GD, Perfetti M, Camastra G.
et al.
Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY study. J Am Coll Cardiol
2017;70:1977–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29025554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio ALP, Pankuweit S, Arbustini E.
et al.
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J
2013;34:2636–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23824828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ismail TF. Acute pericarditis: update on diagnosis and management. Clin Med (Lond)
2020;20:48–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6964178</ArticleId>
            <ArticleId IdType="pubmed">31941732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felker GM, Boehmer JP, Hruban RH.
et al.
Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol
2000;36:227–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10898439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira VM, Schulz-Menger J, Holmvang G.
et al.
Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol
2018;72:3158–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30545455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liguori C, Farina D, Vaccher F, Ferrandino G, Bellini D, Carbone I. Myocarditis: imaging up to date. Radiol Med
2020;125:1124–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7538190</ArticleId>
            <ArticleId IdType="pubmed">33025305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leone O, Veinot JP, Angelini A.
et al.
2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol
2012;21:245–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22137237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh V, Mendirichaga R, Savani GT.
et al.
Comparison of utilization trends, indications, and complications of endomyocardial biopsy in native versus donor hearts (from the Nationwide Inpatient Sample 2002 to 2014). Am J Cardiol
2018;121:356–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29197471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyler Z, Guttmann OP, Dhinoja M.
et al.
The safety and feasibility of transitioning from transfemoral to transradial access left ventricular endomyocardial biopsy. J Invasive Cardiol
2020;32:E349–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33168780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponikowski P, Voors AA, Anker SD.
et al.
2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail
2016;18:891–975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27207191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yancy CW, Jessup M, Bozkurt B.
et al.
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation
2013;128.</Citation>
        </Reference>
        <Reference>
          <Citation>Cooper LT, Baughman KL, Feldman AM.
et al.
The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation
2007;116:2216–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17959655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Jeudy J. Assessment of myocarditis: Cardiac MR, PET/CT, or PET/MR?
Curr Cardiol Rep
2019;21:76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31243587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper LT, Jr. Medical progress: myocarditis. New Engl J Med
2009; 360:1526–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5814110</ArticleId>
            <ArticleId IdType="pubmed">19357408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guzik TJ, Mohiddin SA, Dimarco A.
et al.
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res
2020;116:1666–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7197627</ArticleId>
            <ArticleId IdType="pubmed">32352535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhatt M, Soneja M, Farooqui FA.
et al.
Myocarditis in admitted patients with dengue fever. Infection
2020;48:899–903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32780310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aletti M, Lecoules S, Kanczuga V.
et al.
Transient myocarditis associated with acute Zika virus infection. Clin Infect Dis
2017;64:678–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27940942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol
2016;68:411–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27443438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schultheiss HP, Khl U, Cooper LT. The management of myocarditis. Eur Heart J
2011;32:2616–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21705357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper LT, Hare JM, Tazelaar HD.
et al.
Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol
2008;102:1535–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2613862</ArticleId>
            <ArticleId IdType="pubmed">19026310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merken J, Hazebroek M, Van Paassen P.
et al.
Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy. Circ Heart Fail
2018;11:e004228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29449368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khatib R, Reyes MP, Smith F, Khatib G, Rezkalla S. Enhancement of coxsackievirus B4 virulence by indomethacin. J Lab Clin Med
1990;116:116–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1695914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arfè A, Scotti L, Varas-Lorenzo C.
et al.
Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ
2016;354:i4857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27682515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tschöpe C, Cooper LT, Torre-Amione G, Van Linthout S. Management of myocarditis-related cardiomyopathy in adults. Circ Res
2019;124:1568–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31120823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Georgiopoulos G, Figliozzi S, Sanguineti F.
et al.
Prognostic impact of late gadolinium enhancement by cardiovascular magnetic resonance in myocarditis: a systematic review and meta-analysis. Circ Cardiovasc Imaging
2021;14:e011492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33441003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation
2001;104:1076–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11524405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chareonthaitawee P, Beanlands RS, Chen W.
et al.
Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol
2017;24:1741–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28770463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis – natural history and treatment. N Engl J Med
1997;336:1860–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9197214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bang V, Ganatra S, Shah SP.
et al.
Management of patients with giant cell myocarditis: JACC Review topic of the week. J Am Coll Cardiol
2021;77:1122–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33632487</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
